NCCN Survey: US Cancer Centers Face Generic Oncology Drug Shortages

Survey findings published by the National Comprehensive Cancer Network (NCCN) reveal that generic cancer drug shortfalls continue to disrupt operations across American cancer centers. Survey data gathered in late August 2026 from pharmacy directors and clinical leadership at NCCN Member Institutions show that 100% of responding academic cancer centers are experiencing an active shortage of at least one anti-cancer drug. More than 20% of surveyed institutions report concurrent shortages affecting five or more distinct oncology medications.

NCCN initiated formal tracking of national chemotherapy shortages in June 2023 during widespread supply disruptions involving carboplatin and cisplatin. Data from the September 2026 assessment demonstrate that federal and state regulatory policies have yielded minimal measurable relief. When asked to assess whether legislative or administrative interventions have improved or worsened drug availability since 2023, 96% of surveyed pharmacy directors reported that supply conditions have remained unchanged, while 4% noted improvement.

Specific Agents Affected Across Oncology Care

Supply shortfalls impact essential generic chemotherapies and immunotherapies that serve as standard-of-care foundations across hematology and solid tumor oncology.

Survey results indicate that 94% of responding centers face an active shortage of ifosfamide. Ifosfamide is a generic chemotherapy agent indicated in therapeutic regimens for bladder cancer, ovarian cancer, testicular cancer, uterine cancer, soft tissue sarcoma, osteosarcoma, and multiple pediatric and adult leukemias and lymphomas.

Platin-based chemotherapies remain heavily compromised. Carboplatin shortages affect 71% of surveyed centers, marking a recurrence of supply deficits previously documented in 2023. Cisplatin shortages are reported by 16% of responding institutions. These two agents form the therapeutic backbone for diverse solid tumor malignancies. More than 50% of responding institutions report shortages of intravesical Bacillus Calmette-Guérin (BCG), an essential immunotherapy agent utilized in non-muscle invasive bladder cancer management.

Key Clinical Takeaways for Oncology Nurses: Affected Agents

• Ifosfamide Vulnerability: 94% of academic cancer centers lack adequate supplies of ifosfamide, threatening care continuity across broad pediatric and adult hematology-oncology protocols.
• Platin Supply Instability: 71% of centers report carboplatin deficits and 16% report cisplatin deficits, requiring ongoing vigilance when preparing backbone chemotherapy regimens.
• Immunotherapy Constraints: Over 50% of institutions face restricted supplies of BCG for urologic oncology patients.
• Multi-Drug Depletion: Over 20% of centers manage concurrent shortages across five or more active anti-cancer agents, requiring continuous cross-specialty coordination.

Operational Impacts and Administrative Workload Burdens

To maintain treatment schedules and preserve protocol adherence, 61% of responding cancer centers rely on pharmacy- and physician-led mitigation protocols. These institutional measures include drug waste management initiatives and the adoption of alternative guideline-directed regimens.

Modifications to established patient treatment plans introduce significant administrative complexity. Among centers forced to alter treatment regimens due to drug availability, 90% report requiring repeat prior authorizations from third-party payers. This requirement increases the administrative burden per patient, creating operational bottlenecks and introducing potential delays in clinical care continuity.

NCCN Chief Executive Officer Crystal S. Denlinger, MD, emphasized in a news release that while network institutions have created internal task forces, specialized communication workflows, and institutional strategy groups to preserve patient safety and maintain clinical trial integrity, these operational workarounds divert clinical bandwidth. Resources allocated toward managing supply logistics diminish the time available for direct patient engagement and clinical experience enhancements.

Key Clinical Takeaways for Oncology Nurses: Workflow and Practice

• Prior Authorization Friction: 90% of treatment plan modifications necessitate repeat insurance prior authorizations, directly increasing nursing administrative hours and risking treatment start delays.
• Mitigation Protocol Execution: 61% of centers rely on institutional waste-reduction procedures and substitution guidelines, placing frontline nurses at the center of strict dose-sparing protocols.
• Patient Communication Demands: Internal communication plans are essential to inform patients of regimen alterations, address anxiety surrounding substitute medications, and maintain safety.
• Resource Reallocation: Time spent navigating drug shortages distracts care teams from direct patient care, supportive interventions, and symptom management.

Policy Perspectives and Long-Term Manufacturing Dynamics

Addressing generic drug shortages requires structural reform within pharmaceutical manufacturing supply chains. Alyssa Schatz, DrPH, MSW, NCCN Vice President of Policy & Advocacy, noted in the news release that pharmacy directors strongly advocate for federal economic incentives to encourage high-quality manufacturing of generic oncology therapeutics.

Generic oncology medications are clinically essential yet economically unappealing to commercial manufacturers, creating persistent supply instability. Pharmacy directors surveyed by NCCN called for increased transparency regarding generic drug suppliers and urged manufacturers to provide earlier formal notifications to the U.S. Food and Drug Administration (FDA) when supply disruptions arise.

NCCN continues to collaborate with the End Cancer Drug Shortages Coalition, a group of more than a dozen hematology and oncology non-profit organizations dedicated to advancing long-term policy solutions. In May 2026, the coalition released a joint consensus statement outlining policy proposals to stabilize the generic oncology marketplace.

Reference

1. National Comprehensive Cancer Network. New NCCN survey highlights persistent cancer medication shortages across United States. Press release. Published September 10, 2026. Accessed September 11, 2026. https://www.nccn.org/home/news/newsdetails?NewsId=5624